
Andrey Loboda

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9211006/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor Types. Clinical Cancer Research, 2022, 28, 1680-1689.	7.0	32
2	Reverse Translating Molecular Determinants of Anti–Programmed Death 1 Immunotherapy Response in Mouse Syngeneic Tumor Models. Molecular Cancer Therapeutics, 2022, 21, 427-439.	4.1	10
3	Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials. Clinical Cancer Research, 2022, 28, 2050-2060.	7.0	21
4	Combination of EP ₄ antagonist MF-766 and anti-PD-1 promotes anti-tumor efficacy by modulating both lymphocytes and myeloid cells. Oncolmmunology, 2021, 10, 1896643.	4.6	28
5	Analysis of classical neutrophils and polymorphonuclear myeloid-derived suppressor cells in cancer patients and tumor-bearing mice. Journal of Experimental Medicine, 2021, 218, .	8.5	123
6	ILT3 (LILRB4) Promotes the Immunosuppressive Function of Tumor-Educated Human Monocytic Myeloid-Derived Suppressor Cells. Molecular Cancer Research, 2021, 19, 702-716.	3.4	32
7	Molecular Profiling of Cohorts of Tumor Samples to Guide Clinical Development of Pembrolizumab as Monotherapy. Clinical Cancer Research, 2019, 25, 1564-1573.	7.0	33
8	Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy. Science, 2018, 362,	12.6	1,575
9	Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nature Medicine, 2018, 24, 1449-1458.	30.7	1,071
10	Cancer-Associated Fibroblasts Neutralize the Anti-tumor Effect of CSF1 Receptor Blockade by Inducing PMN-MDSC Infiltration of Tumors. Cancer Cell, 2017, 32, 654-668.e5.	16.8	457
11	IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade. Journal of Clinical Investigation, 2017, 127, 2930-2940.	8.2	2,560
12	Mutational load (ML) and T-cell-inflamed microenvironment as predictors of response to pembrolizumab Journal of Clinical Oncology, 2017, 35, 1-1.	1.6	8
13	Effects of Long-Term Odanacatib Treatment on Bone Gene Expression in Ovariectomized Adult Rhesus Monkeys: Differentiation From Alendronate. Journal of Bone and Mineral Research, 2016, 31, 839-851.	2.8	11
14	Network-driven plasma proteomics expose molecular changes in the Alzheimer's brain. Molecular Neurodegeneration, 2016, 11, 31.	10.8	34
15	Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nature Medicine, 2015, 21, 449-456.	30.7	1,592
16	Pre-Treatment Whole Blood Gene Expression Is Associated with 14-Week Response Assessed by Dynamic Contrast Enhanced Magnetic Resonance Imaging in Infliximab-Treated Rheumatoid Arthritis Patients. PLoS ONE, 2014, 9, e113937.	2.5	18
17	Unique Ectopic Lymph Node-Like Structures Present in Human Primary Colorectal Carcinoma Are Identified by Immune Gene Array Profiling. American Journal of Pathology, 2011, 179, 37-45.	3.8	269
18	A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors. BMC Medical Genomics, 2010, 3, 26	1.5	124

#	Article	IF	CITATIONS
19	Diurnal variation of the human adipose transcriptome and the link to metabolic disease. BMC Medical Genomics, 2009, 2, 7.	1.5	93